Related Experiment Video

Updated: Aug 14, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

Pharmacological treatment and prevention of heart failure in the diabetic patient

Richard W Nesto1

  • 1Department of Cardiovascular Medicine, Lahey Clinic Medical Center, Burlington, Massachusetts, USA.

Reviews in Cardiovascular Medicine
|March 19, 2004
PubMed

Insights

Diabetic cardiomyopathy significantly worsens heart failure prognosis. However, standard heart failure medications, including ACE inhibitors, are effective in diabetic patients, though beta-blockers are underused.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetes mellitus is a significant independent risk factor for heart failure development and poorer prognosis.
  • Diabetic cardiomyopathy, involving myocardial and vascular changes, contributes to adverse outcomes.
  • Current pharmacologic treatments for heart failure in diabetic patients are generally similar to those for non-diabetic patients.

Purpose of the Study:

  • To review the impact of diabetes on heart failure and its treatment.
  • To evaluate the efficacy of standard heart failure pharmacotherapies in diabetic patients.
  • To highlight the underutilization of beta-blockers in this population.

Main Methods:

  • Review of existing literature and subgroup analyses from large clinical trials.
  • Examination of the effects of angiotensin-converting enzyme inhibitors and beta-blockers on heart failure in diabetic patients.
  • Comparison of treatment responses between diabetic and non-diabetic heart failure patients.

Main Results:

  • Diabetic patients experience a poorer prognosis with heart failure, partly due to diabetic cardiomyopathy.
  • Angiotensin-converting enzyme inhibitors reduce mortality and heart failure incidence in diabetic patients.
  • Clinical response to heart failure drugs is similar or superior in diabetic patients compared to non-diabetic patients.
  • Beta-blockers are underused in diabetic patients despite proven efficacy.

Conclusions:

  • Diabetes significantly impacts heart failure outcomes, necessitating careful management.
  • Standard heart failure pharmacotherapies, particularly ACE inhibitors, are beneficial for diabetic patients.
  • Increased utilization of beta-blockers is warranted in diabetic patients with heart failure to improve outcomes.

More Related Videos

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.